BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vumerity (Diroximel fumarate) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vumerity (Diroximel fumarate)\, from Clin
 icalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06319339-6976@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vumerity (Diroximel fumarate): Phase 1 readout est. (NCT06319339)
DESCRIPTION:Vumerity (Diroximel fumarate)\, phase 1.\nStudy: Impact of Nrf2
  Activation on Macrovascular\, Microvascular & Leg Function & Walking Capa
 city in Peripheral Artery Disease\nEstimated primary completion: December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/diroximel-fumar
 ate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06319339
URL:https://assetmemo.bio/drug/diroximel-fumarate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06957808-6976@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20270120
DTEND;VALUE=DATE:20270121
SUMMARY:Vumerity (Diroximel fumarate): Phase na readout est. (NCT06957808)
DESCRIPTION:Vumerity (Diroximel fumarate)\, phase na.\nStudy: Investigating
  the Effect of Diroximel Fumarate on Glutathione in Schizophrenia\nEstimat
 ed primary completion: 20 January 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/diroximel-fumarate#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06957808
URL:https://assetmemo.bio/drug/diroximel-fumarate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07275515-6976@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Vumerity (Diroximel fumarate): Phase 2 readout est. (NCT07275515)
DESCRIPTION:Vumerity (Diroximel fumarate)\, phase 2.\nStudy: DIROXIMEL FUMA
 RATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: DOUBLE 
 BLIND RANDOMIZED CLINICAL TRIAL\nEstimated primary completion: May 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/diroximel-fumarate#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0727551
 5
URL:https://assetmemo.bio/drug/diroximel-fumarate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483632-6976@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20340728
DTEND;VALUE=DATE:20340729
SUMMARY:Vumerity (Diroximel fumarate): Phase 3 readout est. (NCT07483632)
DESCRIPTION:Vumerity (Diroximel fumarate)\, phase 3\, Multiple Sclerosis.\n
 Study: A Study to Learn About the Safety of Diroximel Fumarate (DRF) and D
 imethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Particip
 ants With Relapsing Forms of Multiple Sclerosis (RMS)\nEstimated primary c
 ompletion: 28 July 2034. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/diroximel-fumarate#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07483632
URL:https://assetmemo.bio/drug/diroximel-fumarate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
